HOTH....................................https://stockcharts.com/h-sc/ui?s=HOTH
&p=W&b=5&g=0&id=p86431144783
&p=W&b=5&g=0&id=p86431144783
Recent HOTH News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/27/2026 12:33:47 PM
- Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications • PR Newswire (US) • 05/27/2026 12:11:00 PM
- Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform • PR Newswire (US) • 05/26/2026 12:18:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 08:25:43 PM
- Hoth Therapeutics shares slide after shift toward AI semiconductor strategy (HOTH) • IH Market News • 05/19/2026 01:29:23 PM
- AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagn • PR Newswire (US) • 05/19/2026 12:17:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:06:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 08:07:28 PM
- Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients • PR Newswire (US) • 05/05/2026 08:17:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 09:25:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2026 09:20:01 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/16/2026 09:18:46 PM
- Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide • PR Newswire (US) • 04/14/2026 11:00:00 AM
- Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide • PR Newswire (US) • 04/13/2026 09:23:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:18:12 PM
- Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering • PR Newswire (US) • 04/02/2026 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/02/2026 05:39:13 PM
- Hoth Therapeutics Announces $2.0 Million Registered Direct Offering • PR Newswire (US) • 04/01/2026 05:52:00 PM
- Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six • PR Newswire (US) • 04/01/2026 12:14:00 PM
- Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology • PR Newswire (US) • 03/31/2026 12:07:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/27/2026 08:58:52 PM
- Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery • PR Newswire (US) • 03/26/2026 12:30:00 PM
- Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption • PR Newswire (US) • 03/24/2026 12:13:00 PM
- Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model • PR Newswire (US) • 03/10/2026 12:13:00 PM
- Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program • PR Newswire (US) • 03/04/2026 01:31:00 PM
